Ranolazine
- Generic Name
- Ranolazine
- Brand Names
- Aspruzyo Sprinkle, Ranexa, Ranexa (previously Latixa)
- Drug Type
- Small Molecule
- Chemical Formula
- C24H33N3O4
- CAS Number
- 95635-55-5
- Unique Ingredient Identifier
- A6IEZ5M406
- Background
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
- Indication
Ranolazine is indicated for the treatment of chronic angina. It can be used alone or in conjunction with nitrates, beta-blockers, angiotensin receptor blockers, anti-platelet drugs, calcium channel blockers, lipid-lowering drugs, and ACE inhibitors.
Ranolazine has also been used off-label for the treatment of certain arrhythmias, including ventricular tachycardia, however, this use is not strongly supported by scientific evidence. Ranolazine has also been studied for the treatment of acute coronary syndrome, microvascular coronary dysfunction, arrhythmia, and glycemic control, which are not yet approved indications.
- Associated Conditions
- Chronic Angina, Ventricular Arrhythmia
Feasibility Trial for a Right Ventricular Failure Platform Trial
- Conditions
- Pulmonary HypertensionRight Ventricular DysfunctionRight Heart Failure
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 30
- Registration Number
- NCT06570473
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦University of Alberta, Edmonton, Alberta, Canada
🇨🇦The University of British Columbia, Vancouver, British Columbia, Canada
A Study of Ranolazine in ALS
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Swathy Chandrashekhar, MD
- Target Recruit Count
- 72
- Registration Number
- NCT06527222
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸University of Kansas Medical Center, Fairway, Kansas, United States
Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy
- Conditions
- Inflammatory Bowel DiseaseCrohn's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 4
- Registration Number
- NCT04456517
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy
- Conditions
- HCM - Hypertrophic Non-Obstructive Cardiomyopathy
- Interventions
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 26
- Registration Number
- NCT03953989
- Locations
- 🇮🇹
IRCCS Ospedale San Raffaele, Milan, Italy
Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- OBS Pakistan
- Target Recruit Count
- 2000
- Registration Number
- NCT03486561
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 14
- Registration Number
- NCT03472950
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- TSH Biopharm Corporation Limited
- Target Recruit Count
- 20
- Registration Number
- NCT03401502
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Zhongzheng Dist, Taiwan
RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain
- Conditions
- Ischaemic Myocardial DysfunctionSevere Coronary Artery Disease
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2018-04-10
- Lead Sponsor
- Saint Thomas Health
- Registration Number
- NCT03257683
- Locations
- 🇺🇸
Saint Thomas Heart at Saint Thomas West, Nashville, Tennessee, United States
Comparison of Effectiveness of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
- Conditions
- Atrial FibrillationRecurrence
- Interventions
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Registration Number
- NCT03162120
CiPA Phase 1 ECG Biomarker Validation Study
- Conditions
- PharmacodynamicsDrug-induced QT ProlongationPharmacokinetics
- Interventions
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Food and Drug Administration (FDA)
- Target Recruit Count
- 60
- Registration Number
- NCT03070470
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.